Cargando…
A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)
OBJECTIVES: Oxaliplatin immune-induced syndrome (OIIS) was recently recognized as an uncommon complication of oxaliplatin therapy. METHODS: We report an exceptionally OIIS after pressurized intraperitoneal aerosol chemotherapy (PIPAC). RESULTS: Our patient developed a severe OIIS probably related to...
Autores principales: | Ezanno, Anne-Cecile, Malgras, Brice, Aoun, Olivier, Delarge, Amaury, Doreille, Alice, Pocard, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069496/ https://www.ncbi.nlm.nih.gov/pubmed/35602921 http://dx.doi.org/10.1515/pp-2021-0138 |
Ejemplares similares
-
Reasons for stopping Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): A retrospective study to improve future patient selection
por: Ezanno, Anne-Cécile, et al.
Publicado: (2023) -
Pressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature
por: Ezanno, Anne-Cecile, et al.
Publicado: (2023) -
Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)
por: Sgarbura, Olivia, et al.
Publicado: (2022) -
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework
por: Baggaley, Alice E, et al.
Publicado: (2022) -
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
por: De Simone, Michele, et al.
Publicado: (2020)